Can Bayer challenge Erleada, Xtandi in prostate cancer? by Carly Helfand Friday, February 15, 2019 For years, J&J and Pfizer-Astellas have been the players in their class of prostate-cancer drugs. But strong new safety data could make Bayer a threat.
Merck rolls out 3 new Keytruda prostate cancer studies by Carly Helfand Thursday, February 14, 2019 If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.
Pfizer, Astellas chase new Xtandi nod with big survival numbers by Carly Helfand Tuesday, February 12, 2019 When it comes to Xtandi in hormone-sensitive prostate cancer, Pfizer and Astellas are “really excited." And new data shows they have reason to be.
J&J's Erleada trial stops early on good news by Carly Helfand Thursday, January 31, 2019 J&J is counting on Erleada to carry the prostate cancer baton as Zytiga battles generics. And it just got one step closer to a new indication.
Pfizer's Xtandi blows by Erleada in new prostate cancer field by Carly Helfand Wednesday, January 30, 2019 Xtandi is crushing J&J’s Erleada in the nonmetastatic, castration-resistant prostate cancer market—according to Pfizer executives, at least.
Astellas lays out $255M for gene and cell therapy production by Eric Palmer Wednesday, October 31, 2018 Astellas will invest $255 million in production and R&D as it pushes into gene and cell therapies for cancer and other diseases.
Astellas Oncology picks finalists for C3 cancer care contest by Beth Snyder Bulik Wednesday, September 26, 2018 Astellas narrowed the field of creative cancer care ideas in its annual C3 contest to three finalists who will pitch to an expert panel of judges.
CHMP endorses Lilly's CGRP Emgality, Spark's Luxturna and more by Angus Liu Friday, September 21, 2018 Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.
